Gastrointestinal Stromal Tumors Market is trending with CAGR of 7% by 2023, Key Players- Bayer AG, Novartis AG, Immunicum AB, F. Hoffmann-La Roche Ltd, and AB SCIENCES

The report offers a in depth analysis of the market providing insights into the market dynamics that are required to impact the market positively in the following couple of years.

Global Gastrointestinal Stromal Tumors Market - Overview

One of the most common form of sarcoma is gastrointestinal stromal tumors (GIST) involving the gastrointestinal tract. Gastrointestinal stromal tumors can occur anyplace within the GI tract but is most often found in the stomach i.e. about in 40-70% of the cases and 20-30% in the small intestine. Every year approximately 11 to 20 million people worldwide are diagnosed with GIST.

The gastrointestinal stromal tumors market is expected to grow at a steady pace. The factors influencing the growth of the market include increasing prevalence of gastrointestinal diseases, increasing prevalence of cancer, increasing investments and funding in the field of life science research, increasing awareness among the people, growing geriatric population, changing reimbursement policies and various others.

For Exclusive Sample Copy Visit @ https://www.marketresearchfuture.com/sample_request/1583

The market is forecasted to demonstrate a same growth by 2022, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period 2017 – 2022.

Global Gastrointestinal Stromal Tumors Market - Competitive Analysis

Characterized by the presence of several well-established and small players, the global market of gastrointestinal stromal tumors appears to be highly competitive and fragmented.

There has been increasing development in the field of Gastrointestinal Stromal Tumors. Companies are keen in developing new products for the same. In November 2016, announced supplemental New Drug Application (sNDA) for Stivarga tablets had been submitted for the approval to the U.S. Food and Drug Administration (FDA) for the second-line systemic treatment of patients with unresectable hepatocellular carcinoma (uHCC).

Hepatocellular carcinoma (HCC), is the most common form of liver cancer accounting for more than 70-85 percent of liver cancer across the world. Stivarga is already been approved for the treatment of patients with metastatic gastrointestinal stromal tumor (GIST), metastatic colorectal cancer (mCRC).

For Detailed Reading Visit @  https://www.marketresearchfuture.com/reports/gastrointestinal-stromal-tumors-market-1583

Adding to this in June 2017, Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) the European Medicines Agency recommended regorafenib (oral multi-kinase inhibitor) for the treatment of grownup patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar.

Regorafenib is the only treatment method that has been demonstrated a major improvement in overall survival in second-line hepatocellular carcinoma HCC patients who formerly had no other options for the treatment. The approval of European Commission on the commercial authorization is expected by the end of 2018.

Global Gastrointestinal Stromal Tumors Market - Regional Analysis

Global gastrointestinal stromal tumors market is segmented on the basis of geographies or regions which mainly includes North America, Europe, Asia Pacific, and Middle East & Africa. North America is dominating the global market for gastrointestinal stromal tumors with more than 35% share of the total market in 2016. The major factor for the growth of the market include due to increasing prevalence of liver cancer.

According to Centers for Disease Control and Preventation, every year in the U.S. about 22,000 men & 9,000 women get liver cancer, and more than 16,000 men & 8,000 women die from the same disease.

Europe holds the second largest share of the global gastrointestinal stromal tumors market. Asia Pacific is the fastest growing gastrointestinal stromal tumors stimulation market across the globe.

The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. Whereas, the African region is expected to witness a moderate growth.

Avail Attractive Discount @ https://www.marketresearchfuture.com/check-discount/1583

Major Points form TOC for Gastrointestinal Stromal Tumors Market Research Report – Forecast to 2023

Chapter 1. Report Prologue

Chapter 2. Market Introduction

Chapter 3. Research Methodology

Chapter 4. Market Dynamics

Chapter 5. Market Factor Analysis

Chapter 6. Global Cancer Immunotherapy Market, By Type

Chapter 7. Global Cancer Immunotherapy Market, By Treatment

Chapter 8 Global Cancer Immunotherapy Market, By End User

Chapter 9. Global Cancer Immunotherapy Market, By Region

Chapter 10 Company Landscape

Chapter 11 Company Profiles

Chapter 12 MRFR Conclusion

Chapter 13 Appendix

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.